ES2612259T3 - Inhibidores de cinasa - Google Patents
Inhibidores de cinasa Download PDFInfo
- Publication number
- ES2612259T3 ES2612259T3 ES12809140T ES12809140T ES2612259T3 ES 2612259 T3 ES2612259 T3 ES 2612259T3 ES 12809140 T ES12809140 T ES 12809140T ES 12809140 T ES12809140 T ES 12809140T ES 2612259 T3 ES2612259 T3 ES 2612259T3
- Authority
- ES
- Spain
- Prior art keywords
- nrarb
- cycloalkylene
- alkylene
- ord
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/02—Formic acid
- C07C53/06—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Abstract
Un compuesto de fórmula (I) o una sal farmacéuticamente aceptable del mismo: en la que; W es NH; Y es O; R1 es un grupo seleccionado entre (IIa) - (IIc):**Fórmula** cada uno de R8 y R9 es independientemente hidrógeno o alquilo C1-C6, o R8 y R9 pueden formar junto con el átomo de nitrógeno al que están unidos un sistema anular monocíclico saturado o bicíclico condensado o espiro de 5-11 miembros opcionalmente que contiene un heteroátomo adicional que es oxígeno o nitrógeno, estando dicho átomo de nitrógeno opcionalmente sustituido con alquilo C1-C6; en los que dichos grupos alquilo C1-C6 pueden estar opcionalmente sustituidos con un grupo alquilo C1-C6, cicloalquilo C3-C6, hidroxilo o halo; cada uno de X1, X2, X3, X4 y X5 es independientemente un átomo de carbono, un átomo de nitrógeno, un grupo -(CH)- o un grupo -NH-; de tal forma que cada combinación de los mismos forma un sistema anular aromático; R10 se selecciona entre un grupo que consiste en: hidrógeno, -CN, -NRARB, -N(RC)(alquileno C2-C6)-NRARB, - N(RC)(cicloalquileno C3-C7)-NRARB, -(alquileno C1-C6)-NRARB, -(cicloalquileno C3-C7)-NRARB, -O-(alquileno C2-C6)-NRARB, -O-(cicloalquileno C3-C7)-NRARB, -S-(alquileno C2-C6)-NRARB, -S-(cicloalquileno C3-C7)- NRARB, -N(RC)C(O)-(alquileno C1-C6)-NRARB, -N(RC)C(O)-(cicloalquileno C3-C7)-NRARB, -C(O)N(RC)- (alquileno C2-C6)-NRARB, -C(O)N(RC)-(cicloalquileno C3-C7)-NRARB, -C(O)N(RC)-(alquileno C2-C6)-ORD, - C(O)N(RC)-(cicloalquileno C3-C7)-ORD, -N(RC)C(O)NRARB, -C(O)NRARB, -N(RC)C(O)N(RC)-(alquileno C2-C6)- NRARB, -N(RC)C(O)N(RC)-(cicloalquileno C3-C7)-NRARB, -(alquileno C2-C6)-ORD, -(cicloalquileno C3-C7)-ORD, - O-(alquileno C2-C6)-ORD, -O-(cicloalquileno C3-C7)-ORD, -S-(alquileno C2-C6)-ORD, -S-(cicloalquileno C3-C7)- ORD, -N(RC)S(O)2-(alquileno C1-C6)-NRARB, -N(RC)S(O)2-(cicloalquileno C3-C7)-NRARB, -S(O)2N(RC)- (alquileno C2-C6)-NRARB, -S(O)2N(RC)-(cicloalquileno C3-C7)-NRARB, -S(O)2N(RC)-(alquileno C2-C6)-ORD, - S(O)2N(RC)-(cicloalquileno C3-C7)-ORD, -N(RC)S(O)2-(alquileno C2-C6)-ORD, -N(RC)S(O)2-(cicloalquileno C3- C7)-ORD, -S(O)2N(RARB), -N(RC)S(O)2RD, -N(RC)C(O)RC, -ORC, -SRC, -(heterocicloalquilo C3-C7), (heterocicloalquil C5-C7)-(alquilo C1-C6), (heterocicloalquil C5-C7)(cicloalquil C3-C6)-, y heterocicloalquilcarbonilo C3-C7; en los que cualquiera de dicha porción alquilo C1-C6, cicloalquilo C3-C6, - (alquileno C1-C6)- -(alquileno C2-C6)-, -(cicloalquileno C3-C7)-, -(heterocicloalquilo C3-C7), (heterocicloalquil C5- C7)-(alquilo C1-C6), (heterocicloalquil C5-C7)-(cicloalquilo C3-C6) y (heterocicloalquil C3-C7)carbonilo de los grupos enumerados anteriores puede estar opcionalmente sustituida con un grupo alquilo C1-C6, cicloalquilo C3-C7, hidroxilo o halo; R11 está unido a X4 y se selecciona entre un grupo que consiste en: Hidrógeno; -CN; alquilo C1-C6 que está sustituido con un grupo seleccionado entre -CN, -ORC, -SRC, halo; cicloalquilo C3-C6 que está sustituido con un grupo seleccionado entre alquilo C1-C4, -CN, -ORC, -SRD, halo; -NRARB, -N(RC)(alquileno C2-C6)-NRARB, -N(RC)(cicloalquileno C3-C7)-NRARB, -(alquileno C1-C6)- NRARB, -(cicloalquileno C3-C7)-NRARB, -O-(alquileno C2-C6)-NRARB, -O-(cicloalquileno C3-C7)-NRARB, -S- (alquileno C2-C6)-NRARB, -S-(cicloalquileno C3-C7)-NRARB, -N(RC)C(O)-(alquileno C1-C6)-NRARB, - N(RC)C(O)-(cicloalquileno C3-C7)-NRARB, -C(O)N(RC)-(alquileno C2-C6)-NRARB, -C(O)N(RC)-(cicloalquileno C3-C7)-NRARB, -C(O)N(RC)-(alquileno C2-C6)-ORD, -C(O)N(RC)-(cicloalquileno C3-C7)-ORD, - N(RC)C(O)N(RARB), -C(O)N(RARB), -N(RC)C(O)N(RC)-(alquileno C2-C6)-NRARB, -N(RC)C(O)N(RC)- (cicloalquileno C3-C7)-NRARB, -O-(alquileno C2-C6)-ORD, -O-(cicloalquileno C3-C7)-ORD, -S-(alquileno C2- C6)-ORD, -S-(cicloalquileno C3-C7)-ORD, -N(RC)S(O)2-(alquileno C1-C6)-NRARB, -N(RC)S(O)2-(cicloalquileno C3-C7)-NRARB, -S(O)2N(RC)-(alquileno C2-C6)-NRARB, -S(O)2N(RC)-(cicloalquileno C3-C7)-NRARB, - S(O)2N(RC)-(alquileno C2-C6)-ORD, -S(O)2N(RC)-(cicloalquileno C3-C7)-ORD, -N(RC)S(O)2-(alquileno C2- C6)-ORD, -N(RC)S(O)2(cicloalquileno C3-C7)-ORD, -S(O)2N(RARB), -N(RC)S(O)2RD, -N(RC)C(O)RC, ORC, SRC, -(heterocicloalquilo C3-C7), (heterocicloalquil C5-C7)-(alquilo C1-C6), (heterocicloalquil C5- C7)(cicloalquilo C3-C6) y (heterocicloalquil C3-C7)carbonilo, en los que cualquiera de dicha porción alquilo C1-C6, cicloalquilo C3-C6, - (alquileno C1-C6)- -(alquileno C2-C6)-, -(cicloalquileno C3-C7)-, - (heterocicloalquilo C3-C7), (heterocicloalquil C5-C7)-(alquilo C1-C6), (heterocicloalquil C5-C7)-(cicloalquilo C3-C6) y (heterocicloalquil C3-C7)carbonilo de los grupos enumerados anteriores puede estar opcionalmente sustituida con uno, dos o tres grupos R25 que están independientemente seleccionados de la lista que consiste en: alquilo C1-C6, haloalquilo (C1-C3), hidroxialquilo (C1-C4), cicloalquilo C3-C7, hidroxilo y halo; o R11 está unido a X4 y es fenilo o heteroarilo monocíclico de 5 o 6 miembros, en el que dicho fenilo o heteroarilo monocíclico de 5 o 6 miembros está sustituido con un grupo seleccionado de la lista que consiste en: alquilo C1-C6 que está sustituido con un grupo -CN; cicloalquilo C3-C6 que está sustituido con un grupo seleccionado entre: -CN, -ORC, -SRC o halo; -N(RC)(alquileno C2-C6)-NRARB, -N(RC)(cicloalquileno C3-C7)- NRARB, -(alquileno C1-C6)-NRARB, -(cicloalquileno C3-C7)-NRARB, -O-(cicloalquileno C3-C7)-NRARB, -S- (alquileno C2-C6)-NRARB, -S-(cicloalquileno C3-C7)-NRARB, -N(RC)C(O)-(alquileno C1-C6)-NRARB, -N(RC)C(O)- (cicloalquileno C3-C7)-NRARB, -C(O)N(RC)-(alquileno C2-C6)-NRARB, -C(O)N(RC)-(cicloalquileno C3-C7)-NRARB, -C(O)N(RC)-(alquileno C2-C6)-ORD, -C(O)N(RC)-(cicloalquileno C3-C7)-ORD, -N(RC)C(O)N(RC)-(alquileno C2- C6)-NRARB, -N(RC)C(O)N(RC)-(cicloalquileno C3-C7)-NRARB, -O-(cicloalquileno C3-C7)-ORD, -S-(cicloalquileno C3-C7)-ORD, -N(RC)S(O)2-(alquileno C1-C6)-NRARB, -N(RC)S(O)2-(cicloalquileno C3-C7)-NRARB, -S(O)2N(RC)- (alquileno C2-C6)-NRARB, -S(O)2N(RC)-(cicloalquileno C3-C7)-NRARB, -S(O)2N(RC)-(alquileno C2-C6)-ORD, - S(O)2N(RC)-(cicloalquileno C3-C7)-ORD, -N(RC)S(O)2-(alquileno C2-C6)-ORD, -N(RC)S(O)2-(cicloalquileno C3- C7)-ORD, - N(RC)S(O)2RD, -(heterocicloalquilo C3-C7), (heterocicloalquil C5-C7)-(alquilo C1-C6), (heterocicloalquil C5-C7)(cicloalquilo C3-C6) y (heterocicloalquil C3-C7)carbonilo, en los que cualquiera de dicha porción alquilo C1-C6, cicloalquilo C3-C6, -(alquileno C1-C6)- -(alquileno C2-C6)-, -(cicloalquileno C3-C7)-, -(heterocicloalquilo C3-C7), (heterocicloalquil C5-C7)-(alquilo C1-C6), (heterocicloalquil C5-C7)-(cicloalquilo C3- C6) y (heterocicloalquil C3-C7)carbonilo de los grupos enumerados anteriores puede estar opcionalmente sustituida con uno, dos o tres grupos R25 que se seleccionan independientemente del grupo que consiste en: alquilo C1-C6, haloalquilo (C1-C3), hidroxialquilo (C1-C4), cicloalquilo C3-C7, hidroxilo y halo; RA y RB son, cada vez que aparecen, independientemente hidrógeno, alquilo C1-C6 o cicloalquilo C3-C7, estando dicho alquilo C1-C6 y cicloalquilo C3-C7 opcionalmente sustituidos con un grupo alquilo C1-C3, cicloalquilo C3-C7, -ORD, -CN o halo; como alternativa, RA y RB, pueden formar junto con el átomo de nitrógeno al que están unidos un sistema anular monocíclico o bicíclico heterocíclico saturado de 5-11- miembros que está opcionalmente sustituido con uno o más grupos -ORD, -CN, halo, alquilo C1-C6 o cicloalquilo C3-C7, estando dicho alquilo C1-C6 y cicloalquilo C3-C7 opcionalmente sustituidos con un grupo alquilo C1-C3, cicloalquilo C3-C7, -ORD, -CN o halo; y cuyo anillo monocíclico o bicíclico heterocíclico saturado de 5-11 miembros contiene opcionalmente un heteroátomo adicional que es oxígeno o nitrógeno, dicho átomo de nitrógeno opcionalmente sustituido con alquilo C1-C6 o cicloalquilo C3-C6, en los que cualquiera de dicho alquilo C1-C6 o cicloalquilo C3-C6 puede estar opcionalmente sustituido con un grupo alquilo C1-C6, cicloalquilo C3-C7, -ORD, -CN, o halo; y/o RA y RB puede unirse a un átomo de carbono de la porción - (alquileno C1-C6)-, -(alquileno C2-C6)- o -(cicloalquileno C3-C7)- del grupo unido al nitrógeno al que están conectados para formar un ciclo saturado de hasta 6 átomos en el anillo; Rc es, cada vez que aparece, independientemente hidrógeno, alquilo C1-C6 o cicloalquilo C3-C6, estando dicho alquilo C1-C6 y cicloalquilo C3-C6 opcionalmente sustituidos con un grupo alquilo C1-C3, -ORD, -CN o halo; RD es, cada vez que aparece, independientemente hidrógeno, -CH3 o -C2H5; R12 y R13 son independientemente hidrógeno, alquilo C1-C6, o halógeno; A es un radical cicloalquileno divalente que tiene 5 o 6 átomos en el anillo; estando dicho anillo de cicloalquileno unido a W e Y, y condensado a un anillo de fenilo, estando dicho anillo de fenilo opcionalmente sustituido con uno o dos grupos R24; y en el que dicho radical cicloalquileno divalente tiene la fórmula**Fórmula**
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11192871 | 2011-12-09 | ||
EP12187931 | 2012-10-10 | ||
PCT/EP2012/074446 WO2013083604A1 (en) | 2011-12-09 | 2012-12-05 | Kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2612259T3 true ES2612259T3 (es) | 2017-05-16 |
Family
ID=47471708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12809140T Active ES2612259T3 (es) | 2011-12-09 | 2012-12-05 | Inhibidores de cinasa |
Country Status (35)
Country | Link |
---|---|
US (5) | US8907094B2 (es) |
EP (1) | EP2788349B1 (es) |
JP (1) | JP6128449B2 (es) |
KR (1) | KR101994381B1 (es) |
CN (3) | CN105968110B (es) |
AR (1) | AR089189A1 (es) |
AU (1) | AU2012347350C1 (es) |
BR (1) | BR112014013760A2 (es) |
CA (1) | CA2858447C (es) |
CL (1) | CL2014001486A1 (es) |
CO (1) | CO6970602A2 (es) |
CY (1) | CY1118340T1 (es) |
DK (1) | DK2788349T3 (es) |
EA (1) | EA025268B1 (es) |
ES (1) | ES2612259T3 (es) |
GE (1) | GEP201706735B (es) |
HK (2) | HK1200828A1 (es) |
HR (1) | HRP20161714T1 (es) |
HU (1) | HUE029826T2 (es) |
IL (1) | IL232958A (es) |
LT (1) | LT2788349T (es) |
ME (1) | ME02624B (es) |
MX (1) | MX359200B (es) |
MY (1) | MY170656A (es) |
PE (1) | PE20141370A1 (es) |
PH (1) | PH12014501277A1 (es) |
PL (1) | PL2788349T3 (es) |
PT (1) | PT2788349T (es) |
RS (1) | RS55602B1 (es) |
SG (1) | SG11201402985VA (es) |
SI (1) | SI2788349T1 (es) |
TW (1) | TWI618703B (es) |
UA (1) | UA115320C2 (es) |
WO (1) | WO2013083604A1 (es) |
ZA (1) | ZA201404156B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140103925A (ko) * | 2011-12-09 | 2014-08-27 | 키에시 파르마슈티시 엣스. 피. 에이. | 4-히드록시-1,2,3,4-테트라히드로나프탈렌-1-일 우레아 및 호흡기 질환의 치료에서의 이들의 용도 |
KR20140105459A (ko) * | 2011-12-09 | 2014-09-01 | 키에시 파르마슈티시 엣스. 피. 에이. | 키나아제 억제제 |
WO2013083604A1 (en) | 2011-12-09 | 2013-06-13 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
US20150210722A1 (en) | 2012-08-29 | 2015-07-30 | Respivert Limited | Kinase inhibitors |
EP2890695A2 (en) | 2012-08-29 | 2015-07-08 | Respivert Limited | Kinase inhibitors |
WO2014033449A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
WO2014076484A1 (en) | 2012-11-16 | 2014-05-22 | Respivert Limited | Kinase inhibitors |
EP2970190A1 (en) | 2013-03-14 | 2016-01-20 | Respivert Limited | Kinase inhibitors |
MX363949B (es) * | 2013-04-02 | 2019-04-08 | Topivert Pharma Ltd | Inhibidor de quinasa. |
WO2014162121A1 (en) | 2013-04-02 | 2014-10-09 | Topivert Pharma Limited | Kinase inhibitors based upon n-alkyl pyrazoles |
CA2914457A1 (en) | 2013-06-06 | 2014-12-11 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
US9181242B2 (en) | 2013-06-06 | 2015-11-10 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
US9359354B2 (en) * | 2013-06-06 | 2016-06-07 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
EP2818471A1 (en) * | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5 |
EP3083604A1 (en) | 2013-12-20 | 2016-10-26 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
TWI664967B (zh) | 2014-02-14 | 2019-07-11 | 英商瑞斯比維特有限公司 | 新穎化合物(一) |
MA40775A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 |
US10206949B2 (en) | 2015-09-21 | 2019-02-19 | Ofer Agam | Composition that relieves heartburn, GERD and hangovers |
MA44131A (fr) | 2015-12-23 | 2021-05-26 | Chiesi Farm Spa | Dérivés de 1-(3-tert-butyl-2h-pyrazol-5-yl or 5-tert-butyl-isoxaol-3-yl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalenyl) urée et leur utlisation en tant qu'inhibiteurs de p38 mapk |
AR107163A1 (es) | 2015-12-23 | 2018-03-28 | Chiesi Farm Spa | Inhibidores de quinasa |
AR107165A1 (es) | 2015-12-23 | 2018-03-28 | Chiesi Farm Spa | Inhibidores de quinasa |
EP3440073B1 (en) | 2016-04-06 | 2022-06-08 | Oxular Acquisitions Limited | Kinase inhibitors |
US10364245B2 (en) | 2017-06-07 | 2019-07-30 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
NZ762856A (en) | 2017-10-05 | 2020-07-31 | Fulcrum Therapeutics Inc | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
CN108424372B (zh) * | 2018-05-11 | 2021-08-10 | 浙江华贝药业有限责任公司 | 2,2,2-三氟-n-[(s)-4-羰基四氢萘-1-基]-乙酰胺的纯化工艺 |
CN108707086B (zh) * | 2018-05-15 | 2021-08-10 | 浙江华贝药业有限责任公司 | 一种(1s,4s)-n-(4-羟基四氢萘-1-基)叔丁氧基碳酰胺的纯化工艺 |
AR116628A1 (es) | 2018-10-18 | 2021-05-26 | Syngenta Crop Protection Ag | Compuestos microbiocidas |
KR20220151177A (ko) | 2020-03-05 | 2022-11-14 | 신젠타 크롭 프로텍션 아게 | 살진균 조성물 |
CN112174870B (zh) * | 2020-10-12 | 2023-07-21 | 蔡霈 | (r)-1-烷烃酰基-2-取代吡咯烷-2-甲酰胺的制备方法及其药用用途 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
US5756533A (en) | 1995-03-10 | 1998-05-26 | G.D. Searle & Co. | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
WO1997002289A1 (en) | 1995-07-06 | 1997-01-23 | Zeneca Limited | Peptide inhibitors of fibronectine |
US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
CA2443697A1 (en) * | 2001-04-13 | 2002-10-24 | Pier F. Cirillo | 1,4-disubstituted benzo-fused compounds |
DE60214428T2 (de) | 2001-12-20 | 2007-09-20 | Bayer Healthcare Ag | 1, 4-dihydro-1, 4-diphenylpyridin-derivate |
JP2006504667A (ja) * | 2002-08-08 | 2006-02-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 炎症過程に関与するサイトカインの抑制剤としてのフッ素化フェニル−ナフタレニル−尿素化合物 |
MXPA05008568A (es) | 2003-02-14 | 2005-11-04 | Pfizer Prod Inc | Nuevos compuestos anti-inflamatorios triazolo-piridinas. |
SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
US7880000B2 (en) * | 2004-05-07 | 2011-02-01 | Amgen Inc. | Protein kinase modulators and method of use |
EP1609789A1 (en) | 2004-06-23 | 2005-12-28 | Eli Lilly And Company | Ureido-pyrazole derivatives and their use as kinase inhibitors |
ATE400567T1 (de) | 2004-06-23 | 2008-07-15 | Lilly Co Eli | Kinaseinhibitoren |
GB0418015D0 (en) * | 2004-08-12 | 2004-09-15 | Pfizer Ltd | New compounds |
MX2007001759A (es) | 2004-08-12 | 2007-04-20 | Pfizer | Derivados de triazolopiridinilsulfanilo como inhbidores de proteina quinasa activada por mitogenos. |
US20090215817A1 (en) | 2004-08-18 | 2009-08-27 | Pfizer Inc | Novel Triazolopyridine Compounds for the Treatment of Inflammation |
GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
WO2006133006A2 (en) | 2005-06-03 | 2006-12-14 | Bayer Healthcare Ag | 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents |
US20090012079A1 (en) * | 2006-02-09 | 2009-01-08 | Russell Andrew Lewthwaite | Triazolopyridine Compounds |
CN101146029B (zh) * | 2006-09-13 | 2011-12-28 | 华为技术有限公司 | 一种分组重排序方法和*** |
US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
WO2008043019A1 (en) | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc | 8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression |
US7790741B2 (en) | 2006-10-06 | 2010-09-07 | Abbott Laboratories | Imidazothiazoles and imidazoxazoles |
CN101636397B (zh) | 2007-04-13 | 2012-06-13 | 中国人民解放军军事医学科学院毒物药物研究所 | 脲类化合物、其制备方法及其医药用途 |
US8202899B2 (en) | 2007-07-25 | 2012-06-19 | Array Biopharma Inc. | Pyrazole urea derivatives used as kinase inhibitors |
EP2177505A4 (en) | 2007-08-10 | 2011-08-31 | Astellas Pharma Inc | BICYCLIC ACYLGUANIDINE DERIVATIVE |
TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為pim激酶抑制劑之***吡啶化合物 |
CA2745871C (en) | 2008-12-08 | 2018-02-20 | Gilead Connecticut, Inc. | Imidazopyrazine syk inhibitors |
JP5670912B2 (ja) * | 2008-12-11 | 2015-02-18 | レスピバート・リミテツド | p38MAPキナーゼ阻害剤 |
US8629157B2 (en) | 2009-01-05 | 2014-01-14 | Boehringer Ingelheim International Gmbh | Pyrrolidine compounds which modulate the CB2 receptor |
CN102395586A (zh) * | 2009-02-17 | 2012-03-28 | 奇斯药制品公司 | 作为p38map激酶抑制剂的***并吡啶衍生物 |
WO2010108058A2 (en) | 2009-03-20 | 2010-09-23 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Small molecule inhibitors of dusp6 and uses therefor |
WO2011018916A1 (ja) | 2009-08-12 | 2011-02-17 | コニカミノルタホールディングス株式会社 | 表示パネルの製造方法 |
EP2308866A1 (de) | 2009-10-09 | 2011-04-13 | Bayer CropScience AG | Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide |
GB0921731D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
GB201005589D0 (en) * | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
US9024041B2 (en) * | 2010-04-08 | 2015-05-05 | Respivert Ltd. | P38 MAP kinase inhibitors |
GB201009731D0 (en) * | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
KR20140103925A (ko) | 2011-12-09 | 2014-08-27 | 키에시 파르마슈티시 엣스. 피. 에이. | 4-히드록시-1,2,3,4-테트라히드로나프탈렌-1-일 우레아 및 호흡기 질환의 치료에서의 이들의 용도 |
WO2013083604A1 (en) | 2011-12-09 | 2013-06-13 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
KR20140105459A (ko) | 2011-12-09 | 2014-09-01 | 키에시 파르마슈티시 엣스. 피. 에이. | 키나아제 억제제 |
CA2914457A1 (en) | 2013-06-06 | 2014-12-11 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
US9181242B2 (en) | 2013-06-06 | 2015-11-10 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
US9359354B2 (en) | 2013-06-06 | 2016-06-07 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
-
2012
- 2012-12-05 WO PCT/EP2012/074446 patent/WO2013083604A1/en active Application Filing
- 2012-12-05 GE GEAP201213495A patent/GEP201706735B/en unknown
- 2012-12-05 EP EP12809140.2A patent/EP2788349B1/en active Active
- 2012-12-05 BR BR112014013760A patent/BR112014013760A2/pt not_active Application Discontinuation
- 2012-12-05 DK DK12809140.2T patent/DK2788349T3/en active
- 2012-12-05 EA EA201490949A patent/EA025268B1/ru unknown
- 2012-12-05 PT PT128091402T patent/PT2788349T/pt unknown
- 2012-12-05 ME MEP-2016-279A patent/ME02624B/me unknown
- 2012-12-05 PE PE2014000923A patent/PE20141370A1/es active IP Right Grant
- 2012-12-05 SI SI201230806A patent/SI2788349T1/sl unknown
- 2012-12-05 MY MYPI2014001662A patent/MY170656A/en unknown
- 2012-12-05 HU HUE12809140A patent/HUE029826T2/en unknown
- 2012-12-05 RS RS20170046A patent/RS55602B1/sr unknown
- 2012-12-05 KR KR1020147018237A patent/KR101994381B1/ko active IP Right Grant
- 2012-12-05 PL PL12809140T patent/PL2788349T3/pl unknown
- 2012-12-05 CN CN201610333320.8A patent/CN105968110B/zh not_active Expired - Fee Related
- 2012-12-05 JP JP2014545229A patent/JP6128449B2/ja not_active Expired - Fee Related
- 2012-12-05 SG SG11201402985VA patent/SG11201402985VA/en unknown
- 2012-12-05 CN CN201510853733.4A patent/CN105503861B/zh not_active Expired - Fee Related
- 2012-12-05 UA UAA201406293A patent/UA115320C2/uk unknown
- 2012-12-05 LT LTEP12809140.2T patent/LT2788349T/lt unknown
- 2012-12-05 CA CA2858447A patent/CA2858447C/en not_active Expired - Fee Related
- 2012-12-05 MX MX2014006724A patent/MX359200B/es active IP Right Grant
- 2012-12-05 AU AU2012347350A patent/AU2012347350C1/en not_active Ceased
- 2012-12-05 CN CN201280066480.0A patent/CN104039787B/zh not_active Expired - Fee Related
- 2012-12-05 ES ES12809140T patent/ES2612259T3/es active Active
- 2012-12-07 US US13/708,324 patent/US8907094B2/en not_active Expired - Fee Related
- 2012-12-07 AR ARP120104598A patent/AR089189A1/es not_active Application Discontinuation
- 2012-12-07 TW TW101146036A patent/TWI618703B/zh not_active IP Right Cessation
-
2014
- 2014-06-05 IL IL232958A patent/IL232958A/en active IP Right Grant
- 2014-06-05 CO CO14121392A patent/CO6970602A2/es unknown
- 2014-06-06 CL CL2014001486A patent/CL2014001486A1/es unknown
- 2014-06-06 PH PH12014501277A patent/PH12014501277A1/en unknown
- 2014-06-06 ZA ZA2014/04156A patent/ZA201404156B/en unknown
- 2014-07-14 US US14/330,145 patent/US9145413B2/en not_active Expired - Fee Related
- 2014-10-14 US US14/513,663 patent/US9139584B2/en not_active Expired - Fee Related
-
2015
- 2015-02-06 HK HK15101368.5A patent/HK1200828A1/xx not_active IP Right Cessation
- 2015-02-06 HK HK16110755.6A patent/HK1222647A1/zh not_active IP Right Cessation
- 2015-08-06 US US14/819,722 patent/US9315503B2/en active Active
-
2016
- 2016-04-18 US US15/131,401 patent/US9527846B2/en active Active
- 2016-12-08 CY CY20161101269T patent/CY1118340T1/el unknown
- 2016-12-14 HR HRP20161714TT patent/HRP20161714T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2612259T3 (es) | Inhibidores de cinasa | |
AR123089A2 (es) | Compuesto de piridinona | |
AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
AR096684A1 (es) | Compuestos para tratar atrofia muscular espinal | |
AR085958A1 (es) | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del cns y cancer | |
AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
CO6290657A2 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica | |
AR100691A1 (es) | Esteroides neuroactivos, composiciones, y usos de los mismos | |
AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
AR100442A1 (es) | Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal | |
AR099363A1 (es) | Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil y pirrolo[2,3-d]piridinil acrilamidas | |
AR088235A1 (es) | Derivados de pirazoloquinolina | |
AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
GT201200346A (es) | Derivados de imidazopiridina, su procedimiento de preparaciòn y su aplicaciòn en terapèutica | |
AR076170A1 (es) | Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden. | |
ES2556350T3 (es) | Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos | |
AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR084277A1 (es) | Compuestos utiles para el tratamiento del sida | |
AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
AR096532A1 (es) | Inhibidores de quinasa | |
ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis |